KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eli Lilly (LLY) Gains from Investment Securities (2016 - 2025)

Eli Lilly (LLY) has disclosed Gains from Investment Securities for 17 consecutive years, with $589.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gains from Investment Securities fell 46.78% year-over-year to $589.2 million, compared with a TTM value of $645.0 million through Dec 2025, down 4.73%, and an annual FY2025 reading of $645.0 million, down 4.73% over the prior year.
  • Gains from Investment Securities was $589.2 million for Q4 2025 at Eli Lilly, up from $31.0 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $1.1 billion in Q4 2024 and bottomed at -$643.1 million in Q2 2023.
  • Average Gains from Investment Securities over 5 years is $142.2 million, with a median of $58.6 million recorded in 2021.
  • The sharpest move saw Gains from Investment Securities surged 536.07% in 2021, then crashed 2809.95% in 2023.
  • Year by year, Gains from Investment Securities stood at $189.0 million in 2021, then surged by 40.79% to $266.1 million in 2022, then decreased by 3.72% to $256.2 million in 2023, then soared by 332.16% to $1.1 billion in 2024, then tumbled by 46.78% to $589.2 million in 2025.
  • Business Quant data shows Gains from Investment Securities for LLY at $589.2 million in Q4 2025, $31.0 million in Q3 2025, and $64.1 million in Q2 2025.